← Back to Screener
Exagen Inc. Common Stock (XGN)
Price$2.99
Favorite Metrics
Price vs S&P 500 (26W)-80.62%
Price vs S&P 500 (4W)1.30%
Market Capitalization$74.92M
All Metrics
Book Value / Share (Quarterly)$0.76
P/TBV (Annual)0.62x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)13.48%
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)-53.48%
Gross Margin (TTM)58.28%
Net Profit Margin (TTM)-29.97%
EPS (TTM)$-0.92
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-0.92
Revenue Growth (5Y)9.66%
EPS (Annual)$-0.93
ROI (Annual)-45.92%
Gross Margin (Annual)58.28%
Net Profit Margin (5Y Avg)-52.37%
Cash / Share (Quarterly)$1.41
Revenue Growth QoQ (YoY)21.79%
ROA (Last FY)-34.39%
Revenue Growth TTM (YoY)19.65%
EBITD / Share (TTM)$-0.64
ROE (5Y Avg)-104.06%
Operating Margin (TTM)-21.58%
Cash Flow / Share (Annual)$-0.62
P/B Ratio4.29x
P/B Ratio (Quarterly)7.78x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.03x
Net Interest Coverage (TTM)-3.94x
ROA (TTM)-36.29%
EPS Incl Extra (Annual)$-0.93
Current Ratio (Annual)3.45x
Quick Ratio (Quarterly)3.04x
3-Month Avg Trading Volume0.40M
52-Week Price Return-31.10%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.62
P/S Ratio (Annual)1.13x
Asset Turnover (Annual)1.15x
52-Week High$12.23
Operating Margin (5Y Avg)-48.09%
EPS Excl Extra (Annual)$-0.93
CapEx CAGR (5Y)6.86%
26-Week Price Return-71.87%
Quick Ratio (Annual)3.04x
13-Week Price Return-39.49%
Total Debt / Equity (Annual)1.49x
Current Ratio (Quarterly)3.45x
Enterprise Value$68.707
Revenue / Share Growth (5Y)-1.46%
Asset Turnover (TTM)1.21x
Book Value / Share Growth (5Y)-25.41%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-29.89%
Cash / Share (Annual)$1.41
3-Month Return Std Dev62.81%
Gross Margin (5Y Avg)55.62%
Net Income / Employee (TTM)$-0
ROE (Last FY)-114.34%
Net Interest Coverage (Annual)-3.94x
EPS Basic Excl Extra (Annual)$-0.93
Receivables Turnover (TTM)7.12x
Total Debt / Equity (Quarterly)1.49x
EPS Incl Extra (TTM)$-0.92
Receivables Turnover (Annual)7.12x
ROI (TTM)-50.14%
P/S Ratio (TTM)1.13x
Pretax Margin (5Y Avg)-52.38%
Revenue / Share (Annual)$3.09
Tangible BV / Share (Annual)$2.57
Price vs S&P 500 (52W)-66.19%
Year-to-Date Return-49.34%
5-Day Price Return3.70%
EPS Normalized (Annual)$-0.93
ROA (5Y Avg)-37.31%
Net Profit Margin (Annual)-29.97%
Month-to-Date Return2.67%
Cash Flow / Share (TTM)$-1.45
EBITD / Share (Annual)$-0.64
Operating Margin (Annual)-21.58%
LT Debt / Equity (Annual)1.28x
ROI (5Y Avg)-47.96%
LT Debt / Equity (Quarterly)1.28x
EPS Basic Excl Extra (TTM)$-0.92
P/TBV (Quarterly)0.96x
P/B Ratio (Annual)7.78x
Pretax Margin (TTM)-29.89%
Book Value / Share (Annual)$0.76
Price vs S&P 500 (13W)-42.35%
Beta1.90x
Revenue / Share (TTM)$2.82
ROE (TTM)-126.62%
52-Week Low$2.59
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.18
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
XGNExagen Inc. Common Stock | — | 19.65% | -21.58% | -126.62% | $2.99 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $207.74 |
LHLabcorp Holdings Inc. | 25.31x | 7.25% | 9.92% | 10.28% | $269.19 |
DGXQuest Diagnostics Inc. | 21.75x | 11.78% | 14.10% | 13.88% | $196.31 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $91.07 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $57.85 |
VCYTVeracyte, Inc. | 39.66x | 16.01% | 11.17% | 5.33% | $33.45 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.20 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.29 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.44 |
About
Exagen Inc is a commercial-stage diagnostics company offering ten testing solutions under the Avise brand for autoimmune rheumatic diseases (ARDs). The company's products enable community rheumatologists to accurately diagnose and monitor ARD patients while optimizing treatment decisions. Exagen addresses unmet diagnostic needs in a key therapeutic area.